Platelet function following acute cerebral ischemia

Angiology

Volumn 60, Issue 3, 2009, Pages 362-369

  Smout, Jonathan ^a   Dyker, Alexander ^a   Cleanthis, Marcus ^a   Ford, Gary ^a   Kesteven, Patrick ^a   Stansby, Gererd ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Flow cytometry; Monocyte; Platelet; Stroke

Indexed keywords

D DIMER; PADGEM PROTEIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; FIBRINOGEN;

ACUTE BRAIN DISEASE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MALE; MONOCYTE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; BLOOD; BLOOD CLOTTING PARAMETERS; BRAIN INFARCTION; FLOW CYTOMETRY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PILOT STUDY; REFERENCE VALUE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

AGED; AGED, 80 AND OVER; CEREBRAL INFARCTION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MONOCYTES; P-SELECTIN; PILOT PROJECTS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET COUNT; PLATELET FUNCTION TESTS; REFERENCE VALUES;

EID: 67849119655     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319709332959     Document Type: Article

References (35)

1. Haapaniemi E., Soinne L., Syrjälä M., Kaste M., Tatlisumak T. Serial changes in fibrinolysis and coagulation activation markers in acute and convalescent phase of ischemic stroke. Acta Neurol Scand. 2004 ; 110: 242-247.
2. McCabe D., Harrison P., Mackie I., et al. Platelet degranulation and monocyte-platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack. Br J Haematol. 2004 ; 125: 777-787.
3. Grau AJ, Ruf A., Vogt A., et al. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost. 1998 ; 80: 298-301.
4. Garlichs C., Kozina S., Fateh-Moghadam S., et al. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke. 2003 ; 34: 1412-1418.
5. Yip H., Chen S., Liu J., et al. Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. Stroke. 2004 ; 35: 1683-1687.
6. Marquardt L., Ruf A., Mansmann U., et al. Course of platelet activation markers after ischemic stroke. Stroke. 2002 ; 33: 2570-2574.
7. Belniak-Legiec E., Stelmasiak Z. Blood platelet activation markers in patients with cerebral infarction during the earliest stages of the disease-evaluation using flow cytometry methods. Neurol Neurochir Pol. 2000 ; 34: 853-864.
8. Cha J., Jo W., Shin H., Bae HR, Ho JM, Kim JW Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke. Platelets. 2004 ; 15: 3-7. (Pubitemid 38283214)
9. Tohgi H., Suzuki H., Tamura K., Kimura B. Platelet volume, aggregation, and adenosine triphosphate release in cerebral thrombosis. Stroke. 1991 ; 22: 17-21.
10. Bogousslavsky J., Leclerc J. Platelet glycoprotein IIb/IIIa antagonists for acute ischemic stroke. Neurology. 2001 ; 57 (5 suppl 2). S53 - S57.
11. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001 ; 104: 1533-1537.
12. Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol. 1998 ; 31: 352-358.
13. World Health Organization. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke. 1989 ; 20: 1407-1431.
14. Smout J., Mikhailidis D., Shenton B., Stansby G. Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. Clin Appl Thromb Hemost. 2004 ; 10: 9-18.
15. Li N., Goodall AH, Hjemdahl P. A sensitive flow cytometric assay for circulating platelet-leucocyte aggregates. Br J Haematol. 1997 ; 99: 808-816.
16. Shattil SJ, Cunningham M., Hoxie JA Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood. 1987 ; 70: 307-315.
17. Robless PA, Okonko D., Lintott P., Mansfield AO, Mikhailidis DP, Stansby GP Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2003 ; 25: 16-22.
18. Heptinstall S., May JA, Glenn JR, Sanderson HM, Dickinson JP, Wilcox RG Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Thromb Haemost. 1995 ; 74: 1310-1315.
19. Dougherty JJ, Levy D., Weksler B. Platelet activation in acute cerebral ischaemia. Serial measurements of platelet function in cerebrovascular disease. Lancet. 1977 ; 1: 821-824.
20. Uchiyama S., Yamazaki M., Maruyama S., et al. Shear-induced platelet aggregation in cerebral ischemia. Stroke. 1994 ; 25: 1547-1551.
21. Elwood PC, Beswick A., Pickering J., et al. Platelet tests in the prediction of myocardial infarction and ischaemic stroke: evidence from the Caerphilly Prospective Study. Br J Haematol. 2001 ; 113: 514-520.
22. Lip G., Blann A., Farooqi I., Zarifis J., Sagar G., Beevers DG Abnormal haemorheology, endothelial function and thrombogenesis in relation to hypertension in acute stroke patients: the West Birmingham Stroke Project. Blood Coagul Fibrinolysis. 2001 ; 12: 307-315.
23. Altes A., Abellan M., Mateo J., Avila A., Mart-Vilalta JL, Fontcuberta J. Hemostatic disturbances in acute ischemic stroke: a study of 86 patients. Acta Haematol. 1995 ; 94: 10-15.
24. Lowe G., Rumley A., Whincup P., Danesh J. Hemostatic and rheological variables and risk of cardiovascular disease. Semin Vasc Med. 2002 ; 2: 429-439.
25. Barber M., Langhorne P., Rumley A., Lowe GD, Stott DJ Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke. 1994 ; 35: 1421-1425.
26. Lip G., Blann A., Farooqi I., Zarifis J., Sagar G., Beevers DG Sequential alteration in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. Blood Coagul Fibrinolysis. 2002 ; 13: 339-347.
27. Rothwell P., Howard S., Power D., et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke. 2004 ; 35: 2300-2305.
28. Danesh J., Lewington S., Thompson S., et al. and the Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005 ; 294: 1799-1809.
29. Liu M., Counsell C., Zhao X., Wardlaw J. Fibrinogen depleting agents for acute ischaemic stroke. Cochrane Database Syst Rev. 2003 ; CD00 0091.
30. Coull A., Rothwell P. Underestimation of the early risk of recurrent stroke: evidence of the need for a standard definition. Stroke. 2004 ; 35: 1925-1929.
31. Serebruany V., Malinin A., Ziai W., et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. Stroke. 2005 ; 36: 2289-2292.
32. Diener H., Bogousslavsky J., Brass L., et al. for the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004 ; 364: 331-337.
33. Diener HC, Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 ; 143: 1-13.
34. Eikelboom JW, Hirsh J., Weitz JI, Johnston M., Yi Q., Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002 ; 105: 1650-1655.
35. Helgason C., Bolin K., Hoff J., et al. Development of aspirin resistance in persons with previous ischaemic stroke. Stroke. 1994 ; 25: 2331-2336.